Afina Prativi, Yohannes Wilihelm Saleky, Suparman Suparman, Agustina Indri Hapsari, Gurid Mulyo, Fred Agung

PENGEMBANGAN FORMULA ENTERAL TINGGI BCAA (BRANCHED-CHAIN AMINO ACIDS) BERBAHAN DASAR TEPUNG TEMPE (Rhizopus Oryzae) DAN WHEY PROTEIN ISOLATE UNTUK PASIEN DENGAN SIROSIS HATI

Introduction

Pengembangan formula enteral tinggi bcaa (branched-chain amino acids) berbahan dasar tepung tempe (rhizopus oryzae) dan whey protein isolate untuk pasien dengan sirosis hati . Kembangkan formula enteral tinggi BCAA dari tepung tempe & whey protein isolate untuk pasien sirosis hati. Teliti sifat organoleptik, nutrisi, dan kandungan BCAA produk Hepatolate.

Abstract

Liver cirrhosis is the main cause of morbidity and mortality in chronic liver disease in the world. Conditions that occur in liver cirrhosis include decreased liver function, malnutrition due to inadequate oral intake and impaired absorption which is exacerbated by hypermetabolism and hepatic encephalopathy due to ammonia accumulation, causing a decrease in blood plasma BCAAs. Providing BCAA supplementation provides positive results in patients with liver cirrhosis. This study developed an innovative high-BCAA enteral formula based on tempeh flour and whey protein isolate (Hepatolate).The aim of this study was to evaluate organoleptic properties, nutrient and BCAA content of this product. The research design was experimental, utilizing a completely randomized design with three treatments, conducted at the RSUP Dr. Hasan Sadikin Bandung. The organoleptic properties were tested by 20 semi-trained panelists, and proximate analysis was performed at the Saraswanti Indo Genetech in Padang. The results indicated no significant differences in the organoleptic quality regarding color (p=0.610), aroma (p=0.400), taste (p=0.384), and texture (p=0.067. The best formula being third formulation. Serving size The optimal of Hepatolate is 250 ml, containing 214.42 kcal, 12.05 grams of protein, 4.39 grams of fat, 21.70 grams of carbohydrates, and 3.69 grams of BCAA. The selling price for the best Hepatolate product per serving is IDR 8.899,-. Future research is recommended to assess consumer acceptability, shelf life, and further improvements in the formulation, particularly regarding carbohydrate content.

Review

This paper addresses a critical nutritional challenge in patients with liver cirrhosis, a condition characterized by significant morbidity, malnutrition, and hepatic encephalopathy often exacerbated by BCAA deficiency. The authors propose an innovative solution: the development of a high-BCAA enteral formula, "Hepatolate," utilizing readily available and nutritious ingredients like tempeh flour and whey protein isolate. This approach is highly relevant given the established benefits of BCAA supplementation in this patient population, and the use of natural, cost-effective ingredients holds significant promise for broader application and accessibility, particularly in regions where such ingredients are prevalent. The study employed an experimental design with a completely randomized approach across three formulations, demonstrating a systematic effort to optimize the product. Key objectives included evaluating the organoleptic properties, as well as the nutrient and BCAA content. The results are encouraging, indicating that despite variations in formulation, there were no significant differences in color, aroma, taste, and texture among the prototypes, suggesting good sensory acceptance potential. The identified "best formula" (third formulation) delivers a substantial nutritional profile per 250 ml serving, including 214.42 kcal, 12.05 grams of protein, and notably, 3.69 grams of BCAA, which aligns well with the therapeutic goals for liver cirrhosis patients. The reported low selling price further enhances the product's practical appeal. While the study successfully demonstrates the feasibility of developing a high-BCAA enteral formula with promising nutritional and organoleptic characteristics, it also appropriately identifies crucial areas for future investigation. Recommendations to assess consumer acceptability and shelf life are vital next steps to move this product from formulation to practical application. Furthermore, the suggestion to refine the carbohydrate content indicates a proactive approach to optimizing the formula for specific patient needs. Overall, this research represents a valuable initial step towards providing an accessible and effective nutritional intervention for liver cirrhosis patients, offering a well-supported foundation for subsequent clinical and market evaluations.

Full Text

Comments

You need to be logged in to post a comment.